Nikolaos C.George Ph.D. (Nick)

Partner

(T) + 1.212.326.3887

Connect:

Share

Nick George has been developing and evaluating biologics-based patent portfolios for more than 20 years. He has devised worldwide patent prosecution strategies and evaluated portfolios involving antibodies, antibody drug conjugates, immuno-oncology, cellular therapeutics (including stem cell, natural killer cell, CAR-T, and induced pluripotent stem cell (iPS) therapeutics), antisense and other RNA therapeutics, peptide therapeutics, CRISPR technologies, companion diagnostics, enzyme replacements, and gene therapy, among others.

Nick has developed patent strategies for such marketed products as Fuzeon®, Kynamro®, Fabrazyme®, Syvek®, and Talymed® and for such drug candidates as Celgene and Celularity's cellular therapeutics, Celldex Therapeutics' ErbB3 and KIT antibody clinical candidates, and Kyowa Hakko Kirin's LIGHT antibody portfolio, subsequently licensed to Sanofi in a deal valued at $300+ million. He also has developed patent strategies for such diagnostic products as Phenosense™, GeneSeq™, Replication Capacity™, and the companion diagnostic, Trofile™ (Monogram, now LabCorp).

Nick holds a Ph.D. in genetics from the University of California, Berkeley (1990). Following a postdoctoral fellowship at Columbia University, he joined the legal intern program at his previous firm, during which time he also attended the evening program of Fordham University Law School.

Experience

  • Celgene to be acquired by Bristol-Myers Squibb for approx. $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • Celldex Therapeutics develops worldwide patent portfolios for receptor tyrosine kinase antibody therapeuticsJones Day is developing worldwide patent portfolios for Celldex Therapeutics, Inc.'s receptor tyrosine kinase antibody therapeutics, including anti-ErbB3 and anti-KIT antibody clinical candidates.
  • ToolGen seeks patent protection for CRISPR technologyJones Day is prosecuting patent applications and developing a patent portfolio on behalf of ToolGen, Inc. for CRISPR technology.
  • RaNA Therapeutics (now known as Translate Bio) acquires Shire's messenger RNA therapy platformJones Day acted as IP counsel to RaNA Therapeutics, Inc. (now known as Translate Bio) in connection with its acquisition of Shire Pharmaceuticals' messenger RNA therapy platform (MRT), with lead programs in cystic fibrosis and urea cycle disorders.
  • Celgene develops worldwide patent portfolios covering CAR-T and other cellular therapeuticsJones Day is advising Celgene Corporation in the strategic development of worldwide patent portfolios covering CAR-T and other cellular therapeutics.
  • Celgene develops patent portfolio for anti-CD47 therapeutic antibodiesJones Day represented Celgene Corporation in the development of a portfolio of patents directed to anti-CD47 therapeutic antibodies.
  • Genzyme (Sanofi) develops patent portfolio for antisense drug Kynamro®Jones Day represented Genzyme Corporation (Sanofi) in developing patent portfolios related to the apolipoprotein B-targeting antisense drug, Kynamro® (mipomersen), which was the first antisense drug to reach the market and used for the treatment of homozygous familial hypercholesterolemia.
  • Celgene enters strategic collaboration with MedImmune for hematologic malignanciesJones Day acted as special patent counsel, IP technology transaction counsel, and tax counsel on Celgene Corporation's strategic collaboration with MedImmune regarding human monoclonal antibody MEDI-4736 directed to PD-L1 to allow the immune system to continue to fight blood cancers.
  • Kirin Pharma Kabushiki Kaisha establishes patent portfolio for human LIGHT antibodiesJones Day represented Kirin Pharma Kabushiki Kaisha and Kirin Pharma USA, Inc. in the development of its patent portfolio and prosecution strategies related to human LIGHT antibodies.
  • Trimeris builds patent portfolio for antiviral HIV treatment drug Fuzeon®Jones Day managed Trimeris, Inc.'s patent portfolio and prosecuted key patents related to its antiviral peptide therapeutics, including Fuzeon® (enfuvirtide), a peptide drug co-developed by Trimeris and Hoffmann-LaRoche that represents the first FDA approved member of a new class of HIV therapeutics (fusion inhibitors), and subsequently developed therapeutic peptides.
  • Monogram Biosciences maintains patent portfolio for medicine molecular diagnostics productsJones Day managed a patent portfolio for Monogram Biosciences (now LabCorp) related to individualized medicine molecular diagnostics products, including Phenosense™, GeneSeq™, and Replication Capacity™.
  • Marine Polymer establishes patent portfolio for biopolymeric healthcare products Syvek® and Talymed®Jones Day assisted Marine Polymer Technologies, Inc. in establishing its patent portfolio for Syvek® and Talymed®, biopolymeric healthcare products.
  • BD Diagnostics establishes patent portfolio for molecular diagnostic sepsis testsJones Day represented BD Diagnostics in the establishment of its patent portfolio for molecular diagnostic tests for early prediction of sepsis.
  • Bio-Rad builds patent portfolio for genetic tests for human hemachromatosisJones Day represented Bio-Rad Laboratories, Inc. in connection with its patent portfolio for genetic tests for human hemachromatosis, Bioplex™ 2200 instrumentation for multianalyte detection.
  • PDL BioPharma goes head to head against UCB Pharma in patent interference involving reshaped humanized immunoglobulinsJones Day represented PDL BioPharma, Inc. in patent interference against UCB Pharma S.A. involving "reshaped" humanized immunoglobulins.
  • Mount Sinai School of Medicine develops patent portfolio for genetically engineered negative strand RNA viruses and biological drugs for the treatment of Fabry's DiseaseJones Day represented Mount Sinai School of Medicine of New York University in the establishment of its patent portfolios and prosecution for genetically engineered negative strand RNA viruses (licensed to MedImmune) and biological drugs for the treatment of Fabry's Disease, a genetic disorder (licensed to Genzyme Corp.), including Fabrazyme® (agalsidase beta).
  • IDT settles four-party interference involving antisense technologiesIntegrated Data Technologies, Inc. (IDT) was represented by Jones Day lawyers in connection with a four-party patent interference involving antisense technologies.
  • WellGen develops patent portfolio for nutrigenomics-derived nutraceutical, dietary supplement and food additive productsJones Day managed patent portfolios for WellGen, Inc. covering its nutrigenomics-derived nutraceutical, dietary supplement, and food additive products and uses.
    • View All
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.